Long-acting and extended-release opioids are the only options some patients have for managing pain. FDA is requiring labeling changes aimed at better defining exactly which patients should be candidates for these powerful medications. In addition, manufacturers are being required to conduct studies of their long-term effects.
via FDA Consumer Health Information Updates http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm367660.htm
via FDA Consumer Health Information Updates http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm367660.htm
No comments:
Post a Comment